Canada markets open in 6 hours 13 minutes
  • S&P/TSX

    18,457.78
    +76.82 (+0.42%)
     
  • S&P 500

    3,821.35
    -20.59 (-0.54%)
     
  • DOW

    31,802.44
    +306.14 (+0.97%)
     
  • CAD/USD

    0.7909
    +0.0009 (+0.12%)
     
  • CRUDE OIL

    64.77
    -0.28 (-0.43%)
     
  • BTC-CAD

    67,901.23
    +4,133.53 (+6.48%)
     
  • CMC Crypto 200

    1,081.50
    +57.29 (+5.59%)
     
  • GOLD FUTURES

    1,693.50
    +15.50 (+0.92%)
     
  • RUSSELL 2000

    2,202.98
    +10.77 (+0.49%)
     
  • 10-Yr Bond

    1.5960
    0.0000 (0.00%)
     
  • NASDAQ futures

    12,485.00
    +187.75 (+1.53%)
     
  • VOLATILITY

    25.47
    +0.81 (+3.28%)
     
  • FTSE

    6,692.89
    -26.24 (-0.39%)
     
  • NIKKEI 225

    29,027.94
    +284.69 (+0.99%)
     
  • CAD/EUR

    0.6651
    -0.0011 (-0.17%)
     

Stocks in play: WPD Pharmaceuticals Inc.

Baystreet.ca
·1 min read

Announced that it has engaged Image Analysis Group, a leading medical imaging company, to provide important critical imaging services during the Berubicin phase 2 clinical trials which are scheduled to start in February 2021. IAG has deep expertise in partnering with global biotech companies to provide centralized reading and analysis of patient responses in real time. IAG’s scientific and clinical imaging expertise in the field of glioblastoma multiforme, coupled with IAG’s proprietary Artificial Intelligence (AI) powered platform DYNAMIKA will allow WPD and its partners to review efficacy assessments, objective responses, and to thoroughly explore Berubicin’s effect in patients with GBM. WPD Pharmaceuticals Inc. shares C.WBIO are trading unchanged at $0.32.

Read: